<DOC>
	<DOC>NCT00186394</DOC>
	<brief_summary>To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.</brief_summary>
	<brief_title>High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description>To determine safety and toxicity of a regimen of high dose chemotherapy with allogeneic peripheral blood progenitor cell transplantation; determine the efficacy of the procedure by following clinical outcomes and quality of life measures; and evaluate graft versus host disease incidence and severity with regimen.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<criteria>Morphologically confirmed relapsed nonHodgkin's lymphoma Age: &gt;18 and &lt;61 years of age Signed informed consent Hepatic dysfunction defined by serum transaminases &gt;2.5X normal values Serum creatinine of &gt; 2 mg/dl or creatinine clearance &lt; 60 ml/min Diseases other than nonHodgkin's lymphoma Prior bone marrow transplant procedure Severe psychological or medical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>